SB-705498

Phase 2Small molecule

GSK

SB-705498 is one of 93 small molecule programs targeting Non-Allergic Rhinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Allergic RhinitisActive, not recruiting

Allergic RhinitisActive, not recruiting

MigraineActive, not recruiting

Chronic CoughActive, not recruiting

Non-Allergic RhinitisPhase 2

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

MigrainePhase 2

Active, not recruiting

Chronic CoughPhase 2

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Aimovig

Amgen

Preclinical

33 2

Emgality

Eli Lilly

Preclinical

19 3

Vyepti

Lundbeck

Preclinical

12 4

SB-705498

GSK

Phase 2

1 5

Bayer Aspirin

Bayer

Preclinical

2 6

Savella

AbbVie

Preclinical

2 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 8

Botox

RRevance Therapeutics, Inc.

Preclinical

9 9

Adempas

Bayer

Preclinical

1 10

Viagra

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis2 trials

Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

Completed· GSK logo

GSK·Phase 2·NCT01424397·70 enrolled

SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis

Completed· GSK logo

GSK·Phase 2·NCT01424514·40 enrolled

Non-Allergic Rhinitis1 trial

Intranasal SB-705498 in Non-allergic Rhinitis Patients

Completed· GSK logo

GSK·Phase 2·NCT01439308·40 enrolled

Migraine1 trial

Use Of SB-705498 In The Acute Treatment Of Migraine

Completed· GSK logo

GSK·Phase 2·NCT00269022·70 enrolled

Chronic Cough1 trial

A Study to Investigate the Effect of SB-705498 on Chronic Cough

Completed· GSK logo

GSK·Phase 2·NCT01476098·21 enrolled

ESS1 trial

A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model

Completed· GSK logo

GSK·Phase 1·NCT00731250·45 enrolled

2 more indications

Pain1 trial

Sb-705498 Rectal Pain Study

Terminated· GSK logo

GSK·Phase 2·NCT00461682·1 enrolled

Unspecified1 trial

Intranasal SB-705498 in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00907933·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for SB-705498. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SB-705498 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SB-705498. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

SB-705498

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis2 trials

Non-Allergic Rhinitis1 trial

Migraine1 trial

Chronic Cough1 trial

ESS1 trial

Pain1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News